Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate; immune response elicited in a prime/boost protocol with the glycoprotein B subunit
A canarypox glycoprotein B (ALVAC-gB) recombinant induces human cytomegalovirus-specific neutralizing antibodies and a gB-specific cytotoxic T-lymphocyte response. The priming effect of ALVAC-gB is more efficient than that of the gB subunit in Al(OH)3. Antibodies of IgG2a isotype are induced by ALVA...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
1996
|
| Sorozat: | SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
99 No. Suppl. |
| Tárgyszavak: | |
| mtmt: | 3152243 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/31774 |
| Tartalmi kivonat: | A canarypox glycoprotein B (ALVAC-gB) recombinant induces human cytomegalovirus-specific neutralizing antibodies and a gB-specific cytotoxic T-lymphocyte response. The priming effect of ALVAC-gB is more efficient than that of the gB subunit in Al(OH)3. Antibodies of IgG2a isotype are induced by ALVAC-gB. |
|---|---|
| Terjedelem/Fizikai jellemzők: | 110-112 |
| ISSN: | 0036-5548 |